Ma Yaxi, M.D.


Medical School:Zhejiang University School of Medicine, China

Academic Rank:Chief Physician


Clinical / Research Interests

Gynecological oncology


Uterine cavity lesions

Professional Highlights

Professional Appointments

Education Experience

Research Summary

Therapeutic targets for ovarian carcinoma


JI CAO; Guanyu Lin; Yanling Gong; Peichen Pan; Yaxi Ma; Ping Huang; Meidan Ying; Tingjun Hou; Qiaojun He; Bo Yang*.DNA-PKcs, a novel functional target of acriflavine, mediates acriflavine's p53-dependent synergistic anti-tumor efficiency with melphalan. cancer letters, 2016, 383: 115-124.  

Ma, Yaxi; Cao, Handi; Lou, Siyue; Shao, Xuejing; Lv, Wen; Qi, Xiaotian; Liu, Yujia; Ying, Meidan; He, Qiaojun; Yang, Xiaochun*. Sequential treatment with aurora B inhibitors enhances cisplatin-mediated apoptosis via c-Myc. J Mol Med (Berl), 2015, 93(4): 427-438.  

Qian Zhou; Lei Zhang; Zibo Chen; Pingge Zhao; Yaxi Ma; Bo Yang; Qiaojun He; Meidan Ying* . Small ubiquitin-related modifier-1 modification regulates all-trans-retinoic acid-induced differentiation via stabilization of retinoic acid receptor a. The FEBS Journal, 2014, 281(13): 3032-3047.

Ma Y; Weimer J*; Fredrik R; Adam-Klages S; Sebens S; Caliebe A; Hilpert F; Eckmann-Scholz C; Arnold N; Schem C. Aurora kinase inhibitor AZD1152 has an additional effect of platinum on a   sequential application at the human ovarian cancer cell line SKOV3. Arch Gynecol Obstet, 2013, 8(1): 173-182.

Current Program

Study on the mechanism of DNA-PKcs protein in the DNA crosslinking agent against ovarian cancer in the cooperation with Acriflavine. Funding Source: National Natural Science Foundation of China.

Find People

Search by Family Name

Find A Department

Search by Departments